Edition:
United Kingdom

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.11USD
23 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.11
Open
$1.10
Day's High
$1.12
Day's Low
$1.10
Volume
6,975
Avg. Vol
52,271
52-wk High
$8.20
52-wk Low
$1.10

Chart for

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)
No analyst recommendations are available for .

Overall

Beta: 0.96
Market Cap(Mil.): $6.29
Shares Outstanding(Mil.): 5.66
Dividend: --
Yield (%): --

Financials

  HTBX.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -4.74 -- --
ROI: -197.42 -0.74 13.19
ROE: -245.75 -2.80 15.00

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage:

30 Mar 2018

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

26 Mar 2018

BRIEF-Heat Biologics Files Prospectus Supplement Related To Offering Of Up To $1.3 Million Shares Of Co's Common Stock

* HEAT BIOLOGICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $1.3 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2G2V1vx) Further company coverage: (Reuters.Brief@thomsonreuters.com)

16 Mar 2018

BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1

* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB

28 Feb 2018

BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial

* SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​ Source text: (http://bit.ly/2BG2kXt) Further company coverage:

20 Feb 2018

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

07 Dec 2017

BRIEF-Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​

* Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​

13 Nov 2017

BRIEF-Heat Biologics Inc files for mixed shelf of up to $50 million ‍​

* Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​ Source text - (http://bit.ly/2ltFdsE) Further company coverage:

30 Oct 2017

Competitors

Earnings vs. Estimates